Analyses of survival rate of unresectable pancreatic adenocarcinoma in aspect of data analyses.
نویسندگان
چکیده
Using Cox's proportional hazard model and Weibull's proportional hazard model and taking into account the covariates involved, estimation of survival time was made on 94 confirmed deceased cases of unresectable pancreatic adenocarcinoma (excluding cases of cystadenocarcinoma) from the data of their admission for confirmation of diagnosis. The following results were obtained: 1) The covariates which were related to the prognosis of unresectable pancreatic adenocarcinoma were presence or absence of metastasis to the liver and lung, type of treatment for obstructive jaundice, and whether in such treatment, chemotherapy, or radiotherapy was conducted. 2) Estimation of the survival time after adjusting these factors showed that the median survival time was 57 days in untreated cases with metastasis, 107 days in untreated cases without metastasis, 284 days in cases with metastasis in which surgical treatment for obstructive jaundice, chemotherapy, and radiotherapy was administered, and 350 days in cases without metastasis in which the same positive treatment was administered. It can therefore be deduced that multidisciplinary treatment is effective in prolonging life.
منابع مشابه
Long-Term Progression-Free Survival in a Patient with Locally Advanced, Unresectable Pancreatic Adenocarcinoma
Pancreatic adenocarcinoma is amongst the most lethal malignancies with dismal five-year survival rates. Surgical excision is the mainstay of therapy and unresectable disease is considered incurable. Herein, we describe a patient with unresectable, advanced stage pancreatic adenocarcinoma with a remarkable clinical course following definitive chemoradiotherapy.
متن کاملRegional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial
BACKGROUND Pancreatic cancer is the fourth leading cause of cancer death in the United States. Surgery offers the only chance for cure. However, less than twenty percent of patients are considered operative candidates at the time of diagnosis. A common reason for being classified as unresectable is advanced loco-regional disease.A review of the literature indicates that almost nine hundred pati...
متن کاملEndoscopic Palliation for Unresectable Adenocarcinoma of the Pancreas
Pancreatic cancer is the fourth and the fifth most common cancer in men and women respectively and has the lowest 5-year survival rate of any cancer. The dismal prognosis of patients with pancreatic cancer is mainly due to the late diagnosis and, consequently, the low curative resection rates. While curative resection offers the only chance for longterm survival, 85-90% of the patients are stag...
متن کاملPrognosis following surgical bypass compared with laparotomy alone in unresectable pancreatic adenocarcinoma.
BACKGROUND Resection with curative intent has been shown to prolong survival of patients with locoregional pancreatic ductal adenocarcinoma (PDAC). However, up to 33 per cent of patients are deemed unresectable at exploratory laparotomy owing to unanticipated locally advanced or metastatic disease. In these patients, prophylactic double bypass (PDB) procedures have been considered the standard ...
متن کاملCancer Management Chapter 11: Pancreatic, neuroendocrine GI, and adrenal cancers
LBA4505, 2009). Chemoradiation The addition of chemotherapy to radiation therapy has been shown to improve the survival of patients with unresectable pancreatic adenocarcinoma, with moderate doses of radiation only slightly less effective than higher doses. In a GITSG trial of unresectable disease, moderate-dose radiation (4,000 cGy) with 5-FU chemotherapy significantly improved survival, as co...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Hiroshima journal of medical sciences
دوره 40 2 شماره
صفحات -
تاریخ انتشار 1991